Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Initial High Viral Load Is Associated with Prolonged Shedding of Human Rhinovirus in Allogeneic Hematopoietic Cell Transplant Recipients

Chikara Ogimi1,2,3, Hu Xie4, Wendy M. Leisenring4, Jane M. Kuppers1,5, Keith R Jerome1,5, Angela P. Campbell1,2,3, Janet A. Englund2,3, Michael Boeckh1,4,6, Alpana Waghmare1,2,3,*

1 Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
2 Department of Pediatrics, University of Washington, Seattle, Washington
3 Pediatric Infectious Diseases Division, Seattle Children’s Hospital, Seattle, Washington
4 Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
5 Department of Laboratory Medicine, University of Washington, Seattle, Washington
6 Department of Medicine, University of Washington, Seattle, Washington

ABSTRACT
Recent data suggest human rhinovirus (HRV) is associated with lower respiratory tract infection and mortality in hematopoietic cell transplant (HCT) recipients. Examining risk factors for prolonged viral shedding may provide critical insight for the development of novel therapeutics and help inform infection prevention practices. Our objective was to identify risk factors for prolonged shedding of HRV post-HCT. We prospectively collected weekly nasal samples from allogeneic HCT recipients from day 0 to day 100 post-transplant, and performed real-time reverse transcriptase PCR (December 2005 to February 2010). Subjects with symptomatic HRV infection and a negative test within 2 weeks of the last positive were included. Duration of shedding was defined as time between the first positive and first negative samples. Cycle threshold (Ct) values were used as a proxy for viral load. HRV species were identified by sequencing the 5’ noncoding region. Logistic regression analyses were performed to evaluate factors associated with prolonged shedding (>21 days). We identified 38 HCT recipients with HRV infection fulfilling study criteria (32 adults, 6 children). Median duration of shedding was 9.5 days (range, 2 to 89 days); 18 patients had prolonged shedding. Among 26 samples sequenced, 69% were species A, and species B and C accounted for 15% each; the median shedding duration of HRV did not differ among species (P = .17). Bivariable logistic regression analyses suggest that initial high viral load (low Ct value) is associated with prolonged shedding. HCT recipients with initial high viral loads are at risk for prolonged HRV viral shedding.

© 2018 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

INTRODUCTION
The impact of respiratory viral infections in hematopoietic cell transplant (HCT) recipients is widely appreciated [1–3]. Human rhinoviruses (HRVs) have been increasingly recognized as serious pathogens that are frequently associated with lower respiratory tract infection, mortality and prolonged shedding [4,5]. There is a need for effective antiviral therapy in this population, and new therapeutics are under investigation [6,7]. Defining risk factors for prolonged shedding may provide important information to risk-stratify subjects in antiviral clinical trials with viral load endpoints. Furthermore, risk factors for prolonged viral shedding may inform effective infection prevention practices. The objective of this study was to evaluate viral and host factors associated with prolonged HRV shedding in the upper respiratory tract in HCT recipients.

METHODS
Subjects
We conducted a prospective surveillance study of patients undergoing allogeneic HCT at the Fred Hutchinson Cancer Research Center from December 2005 to February 2010 [8]. For the first 100 days post-transplant, weekly standardized respiratory symptom surveys and viral PCR testing on upper respiratory samples was performed. Only subjects with respiratory symptoms at the time of first HRV detection in the 100 days post-HCT were included in the current study. Subjects were included only if the end of the viral shedding period could be defined, which was if a negative viral PCR test result occurred within 2 weeks of the last positive test [9]. The study was approved by the Institutional Review Board at Fred Hutchinson Cancer Research Center.

Financial disclosure: See Acknowledgments on page 2162.

* Correspondence and reprint requests: Alpana Waghmare, MD, Pediatric Infectious Diseases Division, Seattle Children’s Hospital, 4800 Sand Point Way NE, WA 98105.
E-mail address: alpana.waghmare@seattlechildrens.org (A. Waghmare).
† Present affiliations: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; and Epidemiology and Prevention Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia https://doi.org/10.1016/j.bbmt.2018.07.006
1083-8791/© 2018 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
Laboratory Testing and Definitions

HRV RNA was detected in upper respiratory tract specimens by nucleic acid extraction and real-time reverse transcriptase PCR (RT-PCR). Cycle threshold (Ct) was used as an inverse proxy for viral load, with lower Ct correlating with higher viral load. Sanger sequencing was performed on the 5’ noncoding region using saved nasal samples. The shedding duration was defined as time between the first positive and first negative samples, and prolonged shedding was defined as shedding ≥21 days. Highest daily steroid dose and lowest cell counts in the 2 weeks before first HRV detection were recorded.

Statistical Analysis

Covariates were selected from previously identified risk factors for prolonged shedding of human coronavirus and disease progression of other respiratory viruses, as well as important biological variables thought to influence shedding duration. Continuous covariates (age and Ct) were analyzed as continuous and dichotomous (above and below the median) variables. Univariable and bivariable logistic regression analyses were performed to evaluate associations between covariates and prolonged shedding. Variables with a P value < 0.2 in univariable models were candidates for bivariable models. Mann-Whitney U and Kruskal-Wallis tests were performed to compare continuous values between 2 and more than 2 groups, respectively. Two-sided P values < 0.05 were considered statistically significant. All statistical analyses were performed using SAS 9.4 for Windows (SAS Institute, Cary, NC).

RESULTS

Host and Virologic Characteristics

We identified 38 HCT recipients with HRV infection fulfilling study criteria (32 adults and 6 children) (Table 1). Approximately one half of patients were leukopenic in the 2 weeks before virus detection, but only 1 patient received high-dose steroids (≥ 1 mg/kg/day). The median duration of shedding was 9.5 days (range, 2 to 89 days) and 18 patients (47%) had prolonged shedding (≥21 days). Among 18 patients with Ct values below the median (30.3), 13 (72%) had prolonged shedding. Among 18 patients with prolonged shedding, 2 progressed to lower respiratory tract infection based on positive HRV PCR from bronchoalveolar lavage specimens (on days 21 and 31) during the shedding period; no patient with shorter shedding progressed. Among 26 sequenced nasal samples, 69% were species A, and 15% each were species B and C. The median shedding duration did not differ among species (P = .17) (Supplementary Figure S1). Another 45 patients were asymptomatic at the time of first detection of HRV and the median initial viral load of these 45 patients did not differ from that of the 38 symptomatic patients (P = .92). Among the 45 initially asymptomatic patients, 18 subsequently developed respiratory symptoms during the shedding period (time to development of symptoms: median 14 days; interquartile range, 7 to 37 days) but no patient progressed to lower respiratory tract infection.

Outcome Analyses

Higher viral load (lower Ct value) at onset was associated with longer shedding duration (Figure 1 and Table 1). Bivariable logistic regression analyses indicated that initial Ct below the median (30.3) was consistently associated with prolonged shedding in all models (Figure 2). Similar analyses evaluating Ct as a continuous variable showed consistent results with the exception that the number of transplants was not statistically significant (data not shown). Nonmyeloablative conditioning was associated with prolonged shedding; however, it was no longer statistically significant after adjusting for age at transplantation or number of transplants.

Table 1

Characteristics of Allogeneic HCT Recipients with Rhinovirus Upper Respiratory Tract Infection

|                          | Total (N = 38) | Patients with Prolonged Shedding (n = 18) | Patients with Short-Term Shedding (n = 20) |
|--------------------------|---------------|------------------------------------------|------------------------------------------|
| Female                   | 13 (34)       | 5 (28)                                   | 8 (40)                                   |
| Age, yr                  | 50 (1-71)     | 56 (1-71)                                | 39 (1-62)                                |
| Second transplant        | 7 (18)        | 5 (28)                                   | 2 (10)                                   |
| Donor type               |               |                                          |                                          |
| Related                  | 19 (50)       | 10 (56)                                  | 9 (45)                                   |
| Conditioning regimen     |               |                                          |                                          |
| Nonmyeloablative         | 18 (47)       | 12 (67)                                  | 6 (30)                                   |
| Virologic species        |               |                                          |                                          |
| A                        | 18 (47)       | 10 (56)                                  | 8 (40)                                   |
| B                        | 4 (11)        | 2 (11)                                   | 2 (10)                                   |
| C                        | 4 (11)        | 2 (11)                                   | 2 (10)                                   |
| Unknown                  | 12 (32)       | 4 (22)                                   | 8 (40)                                   |
| Ct value                 | 30.3 (22.4-39.4) | 28.7 (22.4-38.7) | 33.5 (24.2-39.4) |
| Lowest WBC <1,000 cells/μL | 18 (47)       | 7 (39)                                   | 11 (55)                                  |
| Lowest lymphocyte count <100 cells/μL | 17 (45)       | 9 (50)                                   | 8 (40)                                   |
| Lowest neutrophil count <500 cells/μL | 18 (47)       | 8 (44)                                   | 10 (50)                                  |
| Lowest monocyte count <100 cells/μL | 23 (61)       | 11 (61)                                  | 12 (60)                                  |
| Highest daily steroid dose* | 37 (97)       | 18 (100)                                 | 19 (95)                                  |

Data are presented as n (%) or median (range).

* In the 2 weeks before first rhinovirus detection.
Syncytial virus, parainfluenza virus, and inﬂuenza virus are well-established respiratory pathogens including respiratory syncytial virus causing lower respiratory tract infection comparable to that seen with human metapneumovirus. Infection by respiratory viruses is common in the lower respiratory tract, with mortality after inﬂuenza virus infection being more common in older patients and those undergoing a second transplant. Both groups are more likely to have prolonged shedding after adjusting for viral load. We hypothesized that this duration appeared to be similar across all 3 HRV species.

With the widespread use of molecular diagnostics, HRV has been increasingly reported as a serious pathogen in immunocompromised hosts. HRV has been demonstrated to be common in the lower respiratory tract, with mortality after lower respiratory tract infection during periods of prolonged shedding. Our study did not have a large enough sample size to analyze the effect of prolonged shedding on adverse clinical outcomes; further studies are needed to clarify whether prolonged shedding signiﬁcantly affects clinical outcomes.

The growing concern regarding poor outcomes associated with HRV infection following HCT has led to recognition of the need for antiviral agents. Viral shedding duration is often used as an endpoint in clinical trials of new antivirals, and identifying risk factors for prolonged shedding is thus critical for appropriate stratification of patients in randomized trials. However, data on factors associated with prolonged shedding of respiratory viruses are limited, with the exception of inﬂuenza virus in mainly immunocompetent populations and coronavirus in HCT recipients. In the current study, 2 patients developed lower respiratory tract inﬁltration during periods of prolonged shedding. Our study did not have a large enough sample size to analyze the effect of prolonged shedding on adverse clinical outcomes; further studies are needed to clarify whether prolonged shedding signiﬁcantly affects clinical outcomes.

In summary, initial high viral load is a risk factor for prolonged shedding of HRV in HCT recipients, an important ﬁnding for the future design of randomized clinical trials of novel therapeutics with viral load endpoints. These data may also inform effective infection control policies, as the expected HRV shedding duration is ≥21 days in patients with high viral loads.

ACKNOWLEDGMENTS

The authors thank Zachary Stednick for database services; Elizabeth Krantz for statistical support; and Cheryl Callais, Victor Chow, Alex Weiss, Denise Della, Robert Farney, Karin Oesterich, Deborah Reyes, Srilata Remala, Gynevill Jolly, Jennifer Klein, and Christi Dahlgren for sample acquisition.

Financial disclosure: This work was supported by the National Institutes of Health (grant nos. R01 HL081595 [to M.B.], K24 HL093294 [to M.B.], K23 AI114844 [to A.W.], K23 HL091059 [to A.C.], L40 AI071572 [to A.C.], CA18029 [to W.L., clinical database], CA15704 [to H.X.], and T32 HD00723332 [to C.O.]), the Fred Hutchinson Cancer Research Center Vaccine and Infectious Disease Division (biorepository), and the Seattle Children’s Center for Clinical and Translational Research and CTSA grant no. ULI RR025014 (A.C.). Ethical approval was received from Fred Hutchinson institutional research board (IRB #5841).

Conﬂict of interest statement: M.B. received research support (for unrelated research) and served as a consultant for Aviragen; A.W. received research support from Aviragen (for unrelated research). All other authors declare no competing interests.
SUPPLEMENTARY DATA
Supplementary data related to this article can be found online at doi:10.1016/j.bbmt.2018.07.006.

REFERENCES
[1] Chemaly RF, Shah DP, Boeckh MJ. Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies. Clin Infect Dis. 2014;59(suppl 5):S344–S351.
[2] Weigt SS, Gregson AL, Deng JC, Lynch 3rd JP, Belperio JA. Respiratory viral infections in hematopoietic stem cell and solid organ transplant recipients. Semin Respir Crit Care Med. 2011;32:471–493.
[3] Lo MS, Lee GM, Gunawardane N, Burchett SK, Lachenauer CS, Lehmann LE. The impact of RSV, adenovirus, influenza, and parainfluenza infection in pediatric patients receiving stem cell transplant, solid organ transplant, or cancer chemotherapy. Pediatr Transplant. 2013;17:133–142.
[4] Seo S, Waghmare A, Scott EM, et al. Human rhinovirus detection in the lower respiratory tract of hematopoietic cell transplant recipients: association with mortality. Haematologica. 2017;102:1120–1130.
[5] Milano F, Campbell AP, Guthrie KA, et al. Human rhinovirus and coronavirus detection among allogeneic hematopoietic stem cell transplantation recipients. Blood. 2010;115:2088–2094.
[6] Shahani L, Ariza-Heredia EJ, Chemaly RF. Antiviral therapy for respiratory viral infections in immunocompromised patients. Exp Rev Anti Infect Ther. 2017;15:401–415.
[7] Waghmare A, Englund JA, Boeckh M. How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation. Blood. 2016;127:2682–2692.
[8] Campbell AP, Guthrie KA, Englund JA, et al. Clinical outcomes associated with respiratory virus detection before allogeneic hematopoietic stem cell transplant. Clin Infect Dis. 2015;61:192–202.
[9] Ogimi C, Greninger AL, Waghmare AA, et al. Prolonged shedding of human coronavirus in hematopoietic stem cell transplant recipients: risk factors and viral genome evolution. J Infect Dis. 2017;216:203–209.
[10] Martin EK, Kuyers J, Chu HY, et al. Molecular epidemiology of human rhinovirus infections in the pediatric emergency department. J Clin Virol. 2015;62:25–31.
[11] Seo S, Cooley TA, Kuyers JM, et al. Human metapneumovirus infections following hematopoietic cell transplantation: factors associated with disease progression. Clin Infect Dis. 2016;63:178–185.
[12] Kim YJ, Guthrie KA, Waghmare A, et al. Respiratory syncytial virus in hematopoietic cell transplant recipients: factors determining progression to lower respiratory tract disease. J Infect Dis. 2014;209:1195–1204.
[13] Dysangco AT, Kressel AB, Dearth SM, Patel RP, Richards SM. Prolonged rhinovirus shedding in a patient with Hodgkin disease. Infect Control Hosp Epidemiol. 2017;38:500–501.
[14] Kraft CS, Jacob JT, Sears MH, Burd EM, Caliendo AM, Lyon GM. Severity of human rhinovirus infection in immunocompromised adults is similar to that of 2009 H1N1 influenza. J Clin Microbiol. 2012;50:1061–1063.
[15] Jacobs SE, Soave R, Shore TB, et al. Human rhinovirus infections of the lower respiratory tract in hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2013;15:474–486.
[16] Ison MG, Hayden FG, Kaiser L, Corey I, Boeckh M. Rhinovirus infections in hematopoietic stem cell transplant recipients with pneumonia. Clin Infect Dis. 2003;36:1139–1143.
[17] Jalal H, Bibby DF, Bennett J, et al. Molecular investigations of an outbreak of parainfluenza virus type 3 and respiratory syncytial virus infections in a hematology unit. J Clin Microbiol. 2007;45:1690–1696.
[18] Greninger AL, Waghmare A, Adler A, et al. Rule-out outbreak: 24-hour metagenomic next-generation sequencing for characterizing respiratory virus source for infection prevention. J Pediatric Infect Dis Soc. 2017;6:168–172.
[19] Hodson A, Kasiwil M, Streetly M, MacMahon E, Raj K. A parainfluenza-3 outbreak in a SCT unit: sepsis with multi-organ failure and multiple co-pathogens are associated with increased mortality. Bone Marrow Transplant. 2011;46:1545–1550.
[20] Geis S, Priefert C, Weissbrich B, et al. Molecular characterization of a respiratory syncytial virus outbreak in a hematology unit in Heidelberg, Germany. J Clin Microbiol. 2013;51:155–162.
[21] Greninger AL, Zerz DM, Qin X, et al. Rapid metagenomic next-generation sequencing during an investigation of hospital-acquired human parainfluenza virus 3 infections. J Clin Microbiol. 2017;55:177–182.
[22] Cheng FW, Lee V, Shing MM, Li CK. Prolonged shedding of respiratory syncytial virus in immunocompromised children: implication for hospital infection control. J Hosp. Infect. 2008;70:383–385.
[23] U.S. Center for Drug Evaluation and Research. Guidance for Industry Influenza, Developing Drugs for Treatment and/or Prophylaxis. Silver Spring, MD: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; 2009.
[24] Patel P, Bush T, Kojic EM, et al. Duration of influenza virus shedding among HIV-infected adults in the cART era, 2010-2011. AIDS Res Hum Retroviruses. 2016;32:1180–1186.
[25] Winther B, Buchert D, Turner RB, Hendley JO, Tschaikin M. Decreased rhinovirus shedding after intranasal oxymetazoline application in adults with induced colds compared with intranasal saline. Am J Rhinol Allergy. 2010;24:374–377.
[26] Ryoo SM, Kim WY, Sohn CH, et al. Factors promoting the prolonged shedding of the pandemic (H1N1) 2009 influenza virus in patients treated with oseltamivir for 5 days. Influenza Other Respir Viruses. 2013;7:833–837.
[27] Chen Y, Qiao H, Zhang CM, Tong M, Shang S. Risk factors for prolonged shedding of 2009 H1N1 influenza virus. Indian Pediatr. 2011;48:961–963.
[28] Sedlak RH, Nguyen T, Palileo I, Jerome KR, Kuyers J. Superiority of digital reverse transcription-PCR (RT-PCR) over real-time RT-PCR for quantitation of highly divergent human rhinoviruses. J Clin Microbiol. 2017;55:442–449.